A randomized phase III trial of palonosetron plus dexamethasone (day 1) versus palonosetron plus dexamethasone (day 1-3) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy, not including a combination of anthracycline plus cyclophosphamide

被引：0
|
作者：
Sasaki, K. [1 ]
Okita, K. [2 ]
Yuki, S. [3 ]
Takahashi, Y. [4 ]
Abe, M. [5 ]
Hatanaka, K. [6 ]
Isobe, H. [7 ]
Sogabe, S. [8 ]
Oba, K. [9 ]
Komatsu, Y. [10 ]
机构：
[1] Otaru Ekisaikai Hosp, Otaru, Hokkaido, Japan
[2] Sapporo Med Univ Hosp, Sapporo, Hokkaido, Japan
[3] Hokkaido Univ Hosp, Sapporo, Hokkaido 060, Japan
[4] Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[5] Sapporo Kosei Gen Hosp, Sapporo, Hokkaido, Japan
[6] Hakodate Municipal Hosp, Hakodate, Hokkaido, Japan
[7] KKR Sapporo Med Ctr, Sapporo, Hokkaido, Japan
[8] Kushiro Rosai Hosp, Kushiro, Hokkaido, Japan
[9] Hokkaido Univ Hosp, Translat Res & Clin Trial Ctr, Sapporo, Hokkaido 060, Japan
[10] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido 060, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1303
引用
收藏
页码：S267 / S268
页数：2
相关论文
共 50 条
  • [41] Palonosetron versus Granisetron in Combination with Aprepitant and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy: A Single-Institutional Retrospective Cohort Study
    Miyoshi, Takanori
    Miyashita, Hiroo
    Matsuo, Naomi
    Odawara, Miki
    Hori, Minako
    Hiraki, Yoichi
    Kawanaka, Hirofumi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2021, 44 (10) : 1413 - 1418
  • [42] The efficacy of palonosetron/dexamethasone plus NK1 receptor antagonist (aprepitant) therapy for prevention of chemotherapy induced nausea and vomiting in colorectal cancer patients
    Ozaki, Y.
    Horimatsu, T.
    Nozaki, A.
    Hasegawa, S.
    Matsumoto, S.
    Sakai, Y.
    Muto, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S524 - S524
  • [43] Palonosetron (PALO) plus 1-day versus 3-day dexamethasone (DEX) with or without aprepitant against delayed nausea (DN): Pooled analysis for 554 women receiving highly emetogenic chemotherapy (HEC).
    Celio, Luigi
    Longo, Flavia
    Mansueto, Giovanni
    Lapadula, Vittoria
    Agustoni, Francesco
    Aapro, Matti S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Olanzapine and palonosetron without dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: A proof-of-concept trial.
    Kim, Hee Jun
    Ha, Joo Young
    Oh, Edward Hyunseung
    Park, Song Ee
    Yi, Jun Ho
    Jang, Joung Soon
    Hwang, In Gyu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Single-day regimen of palonosetron (PALO) and dexamethasone (DEX) for the prevention of emesis associated with moderately emetogenic chemotherapy (MEC): Subgroup analysis from a randomized phase III trial
    Celio, L.
    Bajetta, E.
    Denaro, A.
    Bichisao, E.
    Frustaci, S.
    Ardizzoia, A.
    Piazza, E.
    Fabi, A.
    Capobianco, A.
    Isa, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy
    Kosaka, Yoshimasa
    Tanino, Hirokazu
    Sengoku, Norihiko
    Minatani, Naoko
    Kikuchi, Mariko
    Nishimiya, Hiroshi
    Waraya, Mina
    Katoh, Hiroshi
    Enomoto, Takumo
    Sato, Takeo
    Kuranami, Masaru
    Watanabe, Masahiko
    SUPPORTIVE CARE IN CANCER, 2016, 24 (03) : 1405 - 1411
  • [47] Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
    Gralla, R
    Lichinitser, M
    Van der Vegt, S
    Sleeboom, H
    Mezger, J
    Peschel, C
    Tonini, G
    Labianca, R
    Macciocchi, A
    Aapro, M
    ANNALS OF ONCOLOGY, 2003, 14 (10) : 1570 - 1577
  • [48] Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy
    Yoshimasa Kosaka
    Hirokazu Tanino
    Norihiko Sengoku
    Naoko Minatani
    Mariko Kikuchi
    Hiroshi Nishimiya
    Mina Waraya
    Hiroshi Katoh
    Takumo Enomoto
    Takeo Sato
    Masaru Kuranami
    Masahiko Watanabe
    Supportive Care in Cancer, 2016, 24 : 1405 - 1411
  • [49] Palonosetron plus dexamethasone for the prevention of emesis induced in patients receiving single and multiple-day high-dose chemotherapy
    Di Nicola, M.
    Mirabile, A.
    Carlo-Stella, C.
    Necchi, A.
    Magni, M.
    Schiavello, E.
    Gianni, A.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S95 - S95
  • [50] Metoclopramide, Dexamethasone, or Palonosetron for Prevention of DelayedChemotherapy-InducedNausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, PhaseIII, Noninferiority Trial
    van der Vorst, Maurice J. D. L.
    Toffoli, Elisa C.
    Beusink, Marlien
    van Linde, Myra E.
    van Voorthuizen, Theo
    Brouwer, Saskia
    van Zweeden, Annette A.
    Vrijaldenhoven, Suzan
    Berends, Johan C.
    Berkhof, Johannes
    Verheul, Henk M. W.
    ONCOLOGIST, 2021, 26 (01): : E173 - E181
12345